| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-04-21 | BAL101553 | treatment refractory tumors | preclinical | Basilea Pharmaceutica (Switzerland) | Cancer - Oncology |
| 2016-04-21 | AFM21, AFM22 (NK- and T-cell TandAbs generated against EGFRvIII) and AFM24 (EGFR/CD16A) | solid tumors | preclinical | Affimed (Germany) | Cancer - Oncology |
| 2016-04-21 | MM-310 | preclinical | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology | |
| 2016-04-21 | bimagrumab (BYM338) | sporadic inclusion body myositis (sIBM) | 2-3 | Novartis (Switzerland) | Inflammatory diseases - Rare diseases |
| 2016-04-21 | BMN 250 - chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulinlike growth factor 2 | mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) | 1-2 | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases |
| 2016-04-21 | OPT-302 | wet age related macular degeneration (AMD) | 1-2a | Opthea (Australia) | Ophtalmological diseases |
| 2016-04-21 | AFM13 in combination with Keytruda® (pembrolizumab) | treatment of Hodgkin lymphoma patients relapsed or refractory to chemotherapy | 1b | Affimed (Germany) | Cancer - Oncology |
| 2016-04-21 | BAL3833 (CCT3833) | preclinical | Basilea Pharmaceutica (Switzerland) | Cancer - Oncology | |
| 2016-04-21 | MD1003 (high doses of pharmaceutical-grade biotin) | chronic visual loss resulting from optic neuritis in multiple sclerosis | 3 | Medday (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2016-04-21 | AFM13 with checkpoint modulators, including checkpoint inhibitor PD-1 | preclinical | Affimed (Germany) | Cancer - Oncology | |
| 2016-04-20 | ZVex™ platform | preclinical | Immune Design (USA - MA) | Cancer - Oncology | |
| 2016-04-20 | Spinraza™ -nusinersen - ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy | 2,3 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2016-04-20 | G100 and ZVex™ platform | non-Hodgkin lymphoma | preclinical | Immune Design (USA - MA) | Cancer - Oncology |
| 2016-04-20 | venetoclax (RG7601, GDC-0199/ABT-199) | relapsed/refractory multiple myeloma | 3 | Abbvie (USA - IL) Genentech, a member of Roche Group (USA - CA - Switzerland) | Cancer - Oncology |
| 2016-04-20 | JCAR016 | WT-1-expressing non-small cell lung cancer (NSCLC), mesothelioma | 1 | Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA) | Cancer - Oncology |
| 2016-04-20 | JCAR018 | Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma | 1 | National Cancer Institute (NCI) Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2016-04-20 | AB-SA01 (phage cocktail targeting Staphylococcus aureus) | Staphylococcus aureus infections in patients with chronic rhinosinusitis | 1 | AmpliPhi BioSciences (USA - VA) | Infectious diseases |
| 2016-04-20 | ALN-TTR02 (patisiran) | transthyretin-mediated amyloidosis (ATTR), familial amyloidotic polyneuropathy (FAP) | 2 | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases |
| 2016-04-20 | ES425 | triple-negative breast cancer (TNBC) | preclinical | Emergent BioSolutions (USA - MD) Aptevo Therapeutics (USA - MD) | Cancer - Oncology |
| 2016-04-20 | CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K | preclinical | Curis (USA - MA) | Cancer - Oncology |
